Advanced prostate cancer patients do not benefit from Reolysin, Taxotere Combo, trial Shows May 19, 2017 Patients with metastatic castration-resistant prostate cancer do not benefit from the addition of Reolysin (pelareorep) to Taxotere (docetaxel), according to recent data from a Phase 2 trial.Read more. Source: Prostate Cancer News Today About Prostate Cancer Advanced Prostate Cancer Clinical Trials Prostate Cancer News Research Treatment Options More for you
Patients with metastatic castration-resistant prostate cancer do not benefit from the addition of Reolysin (pelareorep) to Taxotere (docetaxel), according to recent data from a Phase 2 trial.Read more. Source: Prostate Cancer News Today
About Prostate Cancer Advanced Prostate Cancer Clinical Trials Prostate Cancer News Research Treatment Options
